PATENT CLAIM ANALYSIS

Application Number: 15980325
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "136100"]

Abstract:
The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Claim (Index 1):
An isolated polynucleotide encoding a cross-reactive monoclonal antibody which specifically binds to both IL-17A (SEQ ID NO:2) and IL-17F (SEQ ID NO:4), wherein the monoclonal antibody inhibits the binding of both IL-17A and IL-17F to IL-17RC, and wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-7989.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 93.0
- Lexical Diversity: 1.65789
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13910311', '13539534', '12832311', '11741189', '15208202']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7130190645825194
- 35 USC 102 Novelty (BERT): 0.4837253978424946
- Combined Prediction Score: 0.6900896979085169
- Mean Citation Score: 251.382922
- Max Citation Score: 253.02383
- Similarity Product: 251.63997622968608

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test